- In August 2024, Kura Oncology, Inc., a clinical-stage biopharmaceutical company dedicated to advancing precision medicines for cancer treatment, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for Ziftomenib. This powerful and selective menin inhibitor is being developed for the treatment of advanced gastrointestinal stromal tumors (GIST)
- In September 2021, Zai Lab, an innovative commercial-stage biopharmaceutical company, announced that the Taiwan Food and Drug Administration has approved its New Drug Application (NDA) for QINLOCK (Ripretinib) to treat adult patients with advanced gastrointestinal stromal tumors (GIST) who have previously been treated with three or more kinase inhibitors, including imatinib. QINLOCK specifically targets the wide range of KIT and PDGFRα mutations associated with the progression of GIST
- In May 2020, The U.S. Food and Drug Administration approved Qinlock (Ripretinib) tablets, marking it as the first new drug specifically authorized as a fourth-line treatment for advanced gastrointestinal stromal tumors (GIST), which are tumors that develop in the gastrointestinal tract. Qinlock is intended for adult patients who have previously undergone treatment with three or more kinase inhibitor therapies, including Imatinib
